BACKGROUND: There are many treatment options for metastatic colorectal cancer (CRC). However, to the authors' knowledge, national treatment patterns for metastatic CRC, and the stability of hospital treatment patterns over time, have not been well described. METHODS: Data from the 2006 through 2011 National Cancer Data Base were used to study adults with newly diagnosed metastatic CRC (84,161 patients from 1051 hospitals). Using hierarchical models, the authors characterized hospital volume in the use of different treatment modalities (primary site resection, metastatic site resection, chemotherapy, and palliative care). The authors then assessed variation in the receipt of treatment according to the hospitals' relative volume of services used. Finally, the extent to which hospital treatment patterns changed over the past decade was examined. RESULTS: Overall use of volume of services varied widely (5.0% in the hospitals with low volumes of service to 22.3% in the hospitals with high volumes of service). As hospitals' volumes of services increased, adjusted rates of metastatic site surgery (6.6% to 30.8%; P<.001) and multiagent chemotherapy (37.8% to 57.4%; P<.001) use increased, but primary site resection demonstrated little variation (56.8% vs 59.5%; P = .024). It is interesting to note that use of palliative care also increased (8.1% to 11.3%; P = .002). Hospital treatment patterns did not change over time, with hospitals with high volumes of service consistently using more metastatic site resection and multiagent chemotherapy than hospitals with low volumes of service. CONCLUSIONS: There is wide variation in hospital treatment patterns for patients with metastatic CRC, and these patterns have been stable over time. It appears that much of the approach for metastatic CRC treatment depends on the hospital in which the patient presents.
BACKGROUND: There are many treatment options for metastatic colorectal cancer (CRC). However, to the authors' knowledge, national treatment patterns for metastatic CRC, and the stability of hospital treatment patterns over time, have not been well described. METHODS: Data from the 2006 through 2011 National Cancer Data Base were used to study adults with newly diagnosed metastatic CRC (84,161 patients from 1051 hospitals). Using hierarchical models, the authors characterized hospital volume in the use of different treatment modalities (primary site resection, metastatic site resection, chemotherapy, and palliative care). The authors then assessed variation in the receipt of treatment according to the hospitals' relative volume of services used. Finally, the extent to which hospital treatment patterns changed over the past decade was examined. RESULTS: Overall use of volume of services varied widely (5.0% in the hospitals with low volumes of service to 22.3% in the hospitals with high volumes of service). As hospitals' volumes of services increased, adjusted rates of metastatic site surgery (6.6% to 30.8%; P<.001) and multiagent chemotherapy (37.8% to 57.4%; P<.001) use increased, but primary site resection demonstrated little variation (56.8% vs 59.5%; P = .024). It is interesting to note that use of palliative care also increased (8.1% to 11.3%; P = .002). Hospital treatment patterns did not change over time, with hospitals with high volumes of service consistently using more metastatic site resection and multiagent chemotherapy than hospitals with low volumes of service. CONCLUSIONS: There is wide variation in hospital treatment patterns for patients with metastatic CRC, and these patterns have been stable over time. It appears that much of the approach for metastatic CRC treatment depends on the hospital in which the patient presents.
Authors: Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: John E Scarborough; Ricardo Pietrobon; Kyla M Bennett; Bryan M Clary; Paul C Kuo; Douglas S Tyler; Theodore N Pappas Journal: J Am Coll Surg Date: 2008-02-01 Impact factor: 6.113
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Oncol Date: 2013-10-11 Impact factor: 41.316
Authors: Haejin In; Bridget A Neville; Stuart R Lipsitz; Katherine A Corso; Jane C Weeks; Caprice C Greenberg Journal: Ann Surg Date: 2012-05 Impact factor: 12.969
Authors: Skye C Mayo; Jennifer E Heckman; Andrew D Shore; Hari Nathan; Alexander A Parikh; John F P Bridges; Robert A Anders; Daniel A Anaya; Natasha S Becker; Timothy M Pawlik Journal: Surgery Date: 2011-08 Impact factor: 3.982
Authors: Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Danielle R Heller; Raymond A Jean; Alexander S Chiu; Shelli I Feder; Vadim Kurbatov; Charles Cha; Sajid A Khan Journal: J Gastrointest Surg Date: 2018-09-04 Impact factor: 3.452
Authors: Ellen M Goldberg; Yaniv Berger; Divya Sood; Katherine C Kurnit; Josephine S Kim; Nita K Lee; S Diane Yamada; Kiran K Turaga; Oliver S Eng Journal: Ann Surg Oncol Date: 2021-05-06 Impact factor: 5.344
Authors: Mark A Healy; Jason C Pradarelli; Robert W Krell; Scott E Regenbogen; Pasithorn A Suwanabol Journal: Am J Surg Date: 2016-07-18 Impact factor: 2.565
Authors: Beiqun Zhao; Nicole E Lopez; Samuel Eisenstein; Gabriel T Schnickel; Jason K Sicklick; Sonia L Ramamoorthy; Bryan M Clary Journal: Am J Surg Date: 2019-12-12 Impact factor: 2.565
Authors: Vadim Kurbatov; Benjamin J Resio; Cara A Cama; Danielle R Heller; Charles Cha; Yawei Zhang; Jun Lu; Sajid A Khan Journal: J Gastrointest Oncol Date: 2020-02